Download full-text PDF |
Source |
|---|
Publication Analysis
Top Keywords
Similar Publications
Drug-Drug Interaction Between Rifampicin and Albuvirtide: A Phase 1, Randomized, Open-Label Study.
J Clin Pharmacol
January 2025
Department of Pharmacy, Shanghai Public Health Clinical Center, Fudan University, Shanghai, China.
Albuvirtide (ABT) is a novel long-acting fusion inhibitor for human immunodeficiency virus type 1 (HIV-1), and may be co-administered with rifampicin (RIF) in patients concurrent with tubercle bacillus and HIV-1. This study was conducted to investigate the pharmacokinetic effect of co-administration of the two drugs. In the study, 24 healthy volunteers were randomized to receive ABT alone or with RIF.
View Article and Find Full Text PDFLinezolid Dosing and Pharmacokinetics in North American Patients with Tuberculosis.
Clin Infect Dis
January 2025
Division of Infectious Diseases, Department of Medicine, Vanderbilt University Medical Center, Nashville, TN, USA.
Introduction: Linezolid is recommended in treatment regimens for rifampin- or multi-drug-resistant tuberculosis. However, considerable pharmacokinetic variability exists, and long-term use is limited by adverse effects. This study evaluates the pharmacokinetics of linezolid in patients with tuberculosis from an international therapeutic drug monitoring service.
View Article and Find Full Text PDFDiscovery and biological evaluation of nitrofuranyl-pyrazolopyrimidine hybrid conjugates as potent antimicrobial agents targeting and methicillin-resistant .
RSC Med Chem
December 2024
Natural Products and Medicinal Chemistry Division, CSIR-Indian Institute of Integrative Medicine Canal Road Jammu-180001 India
Nitrofuran and pyrazolopyrimidine-based compounds possess a broad antimicrobial spectrum including Gram-positive and Gram-negative bacteria. In the present work, a series of conjugates of these scaffolds was synthesized and evaluated for antimicrobial activity against and methicillin-resistant (MRSA). Many compounds showed MIC values of ≤2 μg ml, with compound 35 demonstrating excellent activity (MICs: 0.
View Article and Find Full Text PDFClinical application of time-of-flight mass spectrometry nucleic acid detection technology in diagnosis of drug-resistant pulmonary tuberculosis.
Diagn Microbiol Infect Dis
January 2025
Henan Provincial Chest Hospital tuberculosis within Six/Critical Illness Area, Henan Infectious Diseases(TB)Clinical Research Center, Zhengzhou, Henan, 450001, PR China. Electronic address:
Purpose: This study aims to evaluate the clinical diagnostic value of matrix-assisted laser desorption ionization time-of-flight mass spectrometry (MALDI-TOF MS) for tuberculosis and drug-resistant tuberculosis.
Patients And Methods: Totally 201 pulmonary tuberculosis patients were recruited retrospectively. All patients underwent smear microscopy, Mycobacterium growth indicator tube (MGIT) 960 culture, loop-mediated isothermal amplification (LAMP) molecular testing, Xpert MTB/RIF (Xpert), and MassARRAY assay which is a MALDI-TOF MS based method.
Emergence of antibiotic-specific phenotypes during prolonged treatment of mice.
Antimicrob Agents Chemother
January 2025
Rocky Mountain Regional VA Medical Center, Aurora, Colorado, USA.
A major challenge in tuberculosis (TB) therapeutics is that antibiotic exposure leads to changes in the physiology of (), which may enable the pathogen to withstand treatment. While antibiotic-treated has been evaluated in experiments it is unclear if and how long-term treatment with diverse antibiotics with varying treatment-shortening activity (sterilizing activity) affects physiologic processes differently. Here, we used SEARCH-TB, a pathogen-targeted RNA-sequencing platform, to characterize the transcriptome in the BALB/c high-dose aerosol infection mouse model following 4 weeks of treatment with three sterilizing and three non-sterilizing antibiotics.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!